Mitochondrial dysfunction has been identified as a possible early event in
ischemia-
reperfusion damage. The peripheral
benzodiazepine receptor, a mitochondrial inner
membrane protein, has already been proposed to play a role in mitochondrial regulation, although its exact function remains unclear. The aim of this work was to determine the role of peripheral
benzodiazepine receptor in
ischemia-reperfusion injury and to test the potential beneficial effect of a novel potent peripheral
benzodiazepine receptor ligand, 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]
indole-1-
acetamide (
SSR180575). To characterize and link the mitochondrial, cellular, and cardiac consequences of
ischemia-reperfusion, we examined the effects of
SSR180575 in several in vitro and in vivo models of oxidative stress.
Hydrogen peroxide decreased mitochondrial membrane potential, reduced oxidative phosphorylation capacities, and caused
cytochrome c release,
caspase 3 activation, and DNA fragmentation.
SSR180575 (100 nM-1 microM) prevented all these effects. In perfused rat hearts,
SSR180575 administered in vitro (100 nM-1 microM) or by oral pretreatment (3-30 mg/kg) greatly reduced the contractile dysfunction associated with
ischemia-reperfusion. Furthermore, in anesthetized rats,
SSR180575 (3-30 mg/kg p.o.) produced significant reductions in
infarct size after coronary artery occlusion/reperfusion. In conclusion, we have demonstrated that peripheral
benzodiazepine receptor play a major role in the regulation of cardiac
ischemia-reperfusion injury and that
SSR180575, a novel peripheral
benzodiazepine receptor ligand, is of potential interest in these indications.